Glucosamine, an aminosugar inhibiting competitively HGSNAT inhibitor, has shown in vitro proof of concept in fibroblasts from MPS IIIC patients with either missense109 or acceptor splice‐site mutations affecting the HGSNAT gene.110. The gene discussed is HGSNAT; the disease is mucopolysaccharidosis type 3C.